Cannabinoid physiology and pharmacology: 30 years of progress

  title={Cannabinoid physiology and pharmacology: 30 years of progress},
  author={Allyn C. Howlett and Chris S Breivogel and Steven R. Childers and Sam A. Deadwyler and Robert E. Hampson and Linda J. Porrino},

Figures from this paper

The endocannabinoid system and pain.
The roles of anandamide and 2-arachidonoylglycerol, released under physiological conditions, in modulating nociceptive responding at different levels of the neuraxis will be emphasized in this review.
Cannabinoid system in the budgerigar brain
Therapeutic potential of cannabinoid-based drugs.
  • T. Klein, C. Newton
  • Biology, Medicine
    Advances in experimental medicine and biology
  • 2007
Preclinical data with cannabinoid-based drugs suggest efficacy in other inflammatory diseases such as inflammatory bowel disease, Alzheimer's disease, atherosclerosis, and osteoporosis.
Novel therapeutic applications of cannabinoids in cancer disease
The present review shows that cannabinoids exert their anti-cancer effects in a number of ways and in a variety of tissues, and strongly support the idea that cannabinoids may induce benefical effect in cancer treatment.
Functional activity of the cannabinoid 1 receptor is not affected by opioid antagonists in the rat brain
The results suggest that the functional activity of WIN55212-2-stimulated [35S]GTPγS binding was not affected by opioid antagonists in the rat brain membranes, and the results may partially elucidate their actions.
Cannabinoid-Mediated Elevation of Intracellular Calcium: A Structure-Activity Relationship
The present results demonstrate that classic tricyclic cannabinoids with structural similarity to Δ9-THC elicit a robust influx of calcium in T cells putatively through receptor-operated cation channels in a manner sensitive to the cannabinoid receptor antagonists, but independent of the CB1 and CB2 receptors.
High-resolution crystal structure of the human CB1 cannabinoid receptor
The structure of the human CB1 receptor bound to the inhibitor taranabant is determined and it is found that the extracellular surface of CB1, including the highly conserved membrane-proximal N-terminal region, is distinct from those of other lipid-activated GPCRs, forming a critical part of the ligand-binding pocket.
Effects of Fatty Acid Amide Hydrolase Inhibitors Acute Administration on the Positive and Cognitive Symptoms of Schizophrenia in Mice
The present findings clearly indicate that ECS, through an indirect manner, modulates a variety of schizophrenia-like responses in mice.
16 The Endocannabinoid System and its Manifold Central Actions
The aim of this update is to put in a better perspective the cross-talks of endocannabinoids with other signaling molecules, and their implications for the manifold biological activities of these lipids within the central nervous system.


Biosynthesis of an Endogenous Cannabinoid Precursor in Neurons and its Control by Calcium and cAMP
The results thus indicate that NAPE levels in cortical neurons are controlled by Ca2+ ions and cAMP, and regulatory effect may participate in maintaining a supply of cannabimimetic N-acylethanolamines during synaptic activity, and prime target neurons for release of these bioactive lipids.
Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.
A more thorough characterization of the roles of endocannabinoids in health and disease will be necessary to define the significance ofendocannabinoid inactivation mechanisms as targets for therapeutic drugs.
Levels, Metabolism, and Pharmacological Activity of Anandamide in CB1 Cannabinoid Receptor Knockout Mice
A ligand/receptor relationship between AEA and CB1 in these two brain regions, where tonic activation of the receptor may tightly regulate the biosynthesis of its endogenous ligand is suggested.
Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids.
The metabolic pathways suggested so far to underlie the biosynthesis and inactivation of anandamide and 2-AG and the current knowledge of the chemical bases for the interactions of an andamide with proteins of the endogenous cannabinoid system characterized so far are reviewed.
Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells.
  • K. Mackie, B. Hille
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1992
It is found that cannabinoid receptor activation reduces the amplitude of voltage-gated calcium currents in the neuroblastoma-glioma cell line NG108-15, suggesting that inhibition of N-type calcium channels, which could decrease excitability and neurotransmitter release, may underlie some of the psychoactive effects of cannabinoids.
Cannabinoid receptors: G-protein-mediated signal transduction mechanisms.
It is clear that these receptor-effector combinations are well situated to mediate many of the well-known neurobiological effects of delta 9-THC.
Role of endogenous cannabinoids in synaptic signaling.
The synthetic pathways of endocannabinoids are discussed, along with the putative mechanisms of their release, uptake, and degradation, and the fine-grain anatomical distribution of the neuronal cannabinoid receptor CB1 is described in most brain areas, emphasizing its general presynaptic localization and role in controlling neurotransmitter release.
Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids.
  • L. Sim-Selley
  • Biology, Psychology
    Critical reviews in neurobiology
  • 2003
Marijuana produces a number of characteristic behaviors in humans and animals, including memory impairment, antinociception, and locomotor and psychoactive effects. However, tolerance and dependence
Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells.
It is shown that, although anandamide inhibits N-type ICa via a PTX-sensitive G protein, its action as a neuromodulator in the intact animal may be more complex than would be inferred by extrapolating the results of in vivo studies with (-)-delta 9-tetra-hydrocannabinol or synthetic cannabinoids.
Downregulation of rat brain cannabinoid binding sites after chronic Δ 9-tetrahydrocannabinol treatment